ALK translocated lung cancers are a heterogeneous group of tumors, and it is now pivotal to evaluate ALK-positive NS-NSCLC at baseline in the context of their genomic background in order to more clearly predict the behavior of tumors before targeted therapy [72,82]. However, the robustness ...